Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine.

Kharasch E.D., Hoffer C., Whittington D., Sheffels P. (2003) Role of P-glycoprotein in the intestinal absorption and clinical effects of morphine. Clinical pharmacology and therapeutics, 74(6):543-54.

 PubMed


Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients.

Fitzgibbon D., Morgan D., Dockter D., Barry C., Kharasch E.D. (2003) Initial pharmacokinetic, safety and efficacy evaluation of nasal morphine gluconate for breakthrough pain in cancer patients. Pain, 106(3):309-15.

 PubMed


Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line.

Altuntas T.G., Zager R.A., Kharasch E.D. (2003) Cytotoxicity of S-conjugates of the sevoflurane degradation product fluoromethyl-2,2-difluoro-1-(trifluoromethyl) vinyl ether (Compound A) in a human proximal tubular cell line. Toxicology and applied pharmacology, 193(1):55-65.

 PubMed


Determination of morphine and morphine glucuronides in human plasma by 96-well plate solid-phase extraction and liquid chromatography-electrospray ionization mass spectrometry.

Whittington D., Kharasch E.D. (2003) Determination of morphine and morphine glucuronides in human plasma by 96-well plate solid-phase extraction and liquid chromatography-electrospray ionization mass spectrometry. Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 796(1):95-103.

 PubMed


Safety of low-flow sevoflurane anesthesia in patients with chronically impaired renal function is not proven.

Saidman L.J., Eger E.I., Kharasch E.D., Conzen P., Michalowski P., Weiss B.M., Rooke G.A., Artru A., Ebert T., Czerner S.F.A., Reichle F.M. (2003) Safety of low-flow sevoflurane anesthesia in patients with chronically impaired renal function is not proven. Anesthesiology, 99(3):752; author reply 752-4.

 PubMed


CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease.

Emery M.G., Fisher J.M., Chien J.Y., Kharasch E.D., Dellinger E.P., Kowdley K.V., Thummel K.E. (2003) CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology (Baltimore, Md.), 38(2):428-35.

 PubMed


Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats.

Spracklin D.K., Emery M.E., Thummel K.E., Kharasch E.D. (2003) Concordance between trifluoroacetic acid and hepatic protein trifluoroacetylation after disulfiram inhibition of halothane metabolism in rats. Acta anaesthesiologica Scandinavica, 47(6):765-70.

 PubMed


Acute intravascular volume expansion with rapidly administered crystalloid or colloid in the setting of moderate hypovolemia.

McIlroy D.R., Kharasch E.D. (2003) Acute intravascular volume expansion with rapidly administered crystalloid or colloid in the setting of moderate hypovolemia. Anesthesia and analgesia, 96(6):1572-7, table of contents.

 PubMed


Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19.

Yao C., Kunze K.L., Trager W.F., Kharasch E.D., Levy R.H. (2003) Comparison of in vitro and in vivo inhibition potencies of fluvoxamine toward CYP2C19. Drug metabolism and disposition: the biological fate of chemicals, 31(5):565-71.

 PubMed


Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.

Ibrahim A.E., Feldman J., Karim A., Kharasch E.D. (2003) Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil. Anesthesiology, 98(4):853-61.

 PubMed


Gender differences in drug effects: implications for anesthesiologists.

Pleym H., Spigset O., Kharasch E.D., Dale O. (2003) Gender differences in drug effects: implications for anesthesiologists. Acta anaesthesiologica Scandinavica, 47(3):241-59.

 PubMed


Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity.

Kharasch E.D., Hoffer C., Walker A., Sheffels P. (2003) Disposition and miotic effects of oral alfentanil: a potential noninvasive probe for first-pass cytochrome P4503A activity. Clinical pharmacology and therapeutics, 73(3):199-208.

 PubMed